The management of diabetes in women with gestational diabetes and in children and adolescents with type 1 diabetes presents challenges that require therapeutic options that address the unique needs of these patients. Technosphere® insulin (TI), the main component of the Afrezza® Inhalation System, has the potential to address these challenges by improving glycemic management, reducing hypoglycemia, and promoting treatment adherence. TI is characterized by a rapid onset of action and a short duration of effect, distinguishing it from traditional injectable rapid-acting insulin analogs. This article discusses greater flexibility in insulin delivery, along with potential applications, benefits, and challenges of treatment with Technosphere inhaled insulin in these two patient populations.
PeyrotM, BarnettAH, MeneghiniLF, Schumm-DraegerPM. Insulin adherence behaviors and barriers in the multinational Global Attitudes of Subjects and Physicians in Insulin Therapy study. Diabet Med, 2012; 29(5):682–689.
2.
LiuC, De RozaJ, OoiCW, et al.Impact of patients’ beliefs about insulin on acceptance and adherence to insulin therapy: A qualitative study in primary care. BMC Prim Care, 2022; 23(1):15; doi: 10.1186/s12875-022-01627-9
3.
MazzottaFA, Lucaccini PaoliL, RizziA, et al.Unmet needs in the treatment of type 1 diabetes: Why is it so difficult to achieve an improvement in metabolic control? Nutr Diabetes, 2024; 14(1):58; doi: 10.1038/s41387-024-00319-w
4.
HeinemannL, BaughmanR, BossA, HompeschM. Pharmacokinetic and pharmacodynamic properties of a novel inhaled insulin. J Diabetes Sci Technol, 2017; 11(1):148–156; doi: 10.1177/1932296816658055
BeckRW, BaileyRJ, AkturkHK, et al.; INHALE-3 Study Group. A 13-week single-arm evaluation of inhaled technosphere insulin plus insulin Degludec for adults with type 1 diabetes. Diabetes Technol Ther, 2025; 27(3):161–169; doi: 10.1089/dia.2024.0581
7.
BeckRW, BaileyRJ, KleinKR, et al.; INHALE-3 Study Group. Inhaled technosphere insulin plus insulin degludec for adults with type 1 diabetes: The INHALE-3 Extension Study. Diabetes Technol Ther, 2025; 27(3):170–178; doi: 10.1089/dia.2024.0582
8.
JacobsonC, KaisermanKB, UlloaJ, et al.Safety and efficacy of inhaled Technosphere® insulin in the postprandial period with modified initial dose conversion. Diabetes Ther, 2025; 16(8):1695–1705; doi: 10.1007/s13300-025-01760-5
9.
HallerMJ, JonesMC, BhavsarS, KaisermanKB. Time-action profile of technosphere insulin in children with type 1 diabetes. Diabetes Ther, 2023; 14(3):611–617; doi: 10.1007/s13300-023-01368-7
10.
GrantM, HeiseT, BaughmanR. Comparison of pharmacokinetics and pharmacodynamics of inhaled technosphere insulin and subcutaneous insulin Lispro in the treatment of type 1 diabetes mellitus. Clin Pharmacokinet, 2022; 61(3):413–422.
11.
KaisermanKB, ChristiansenM, BhavsarS, et al.Reduction in postprandial peak glucose with increased technosphere insulin dosage. J Diabetes Sci Technol, 2024; 18(2):397–401; doi: 10.1177/19322968221110622
12.
AkturkHK, Snell-BergeonJK, RewersA, et al.Improved postprandial glucose with inhaled technosphere insulin compared with insulin aspart in patients with type 1 diabetes on multiple daily injections: The STAT Study. Diabetes Technol Ther, 2018; 20(10):639–647; doi: 10.1089/dia.2018.0200
13.
SaravananP, Diabetes in Pregnancy Working Group, Medicine Clinical Study Group, Royal College of Obstetricians and Gynaecologists, UK. Gestational diabetes: Opportunities for improving maternal and child health. Lancet Diabetes Endocrinol, 2020; 8(9):793–800; doi: 10.1016/S2213-8587(20)30161-3
14.
SweetingA, WongJ, MurphyHR, RossGP. A clinical update on gestational diabetes mellitus. Endocr Rev, 2022; 43(5):763–793; doi: 10.1210/endrev/bnac003
National Center for Health Statistics, National Vital Statistics System, Natality Data. Available from: https://www.cdc.gov/nchs/nvss/births.htm [Last accessed: June24, 2025].
17.
MetzgerBE, GabbeSG, PerssonB, et al.; International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care, 2010; 33(3):676–682; doi: 10.2337/dc09-1848
18.
CarpenterMW, CoustanDR. Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol, 1982; 144(7):768–773; doi: 10.1016/0002-9378(82)90349-0
19.
CrowtherCA, HillerJE, MossJR, et al.; Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med, 2005; 352(24):2477–2486; doi: 10.1056/NEJMoa042973
20.
LandonMB, SpongCY, ThomE, et al.; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med, 2009; 361(14):1339–1348; doi: 10.1056/NEJMoa0902430
21.
FarrarD, SimmondsM, BryantM, et al.Hyperglycaemia and risk of adverse perinatal outcomes: Systematic review and metaanalysis. Obstet Anesthes Dig, 2017; 37(2):64–65.
22.
FarrarD. Hyperglycemia in pregnancy: Prevalence, impact, and management challenges. Int J Womens Health, 2016; 8:519–527.
23.
YeW, LuoC, HuangJ, et al.Gestational diabetes mellitus and adverse pregnancy outcomes: Systematic review and meta-analysis. Bmj, 2022; 377:e067946; doi: 10.1136/bmj-2021-067946
MetzgerBE, LoweLP, DyerAR, et al.; HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med, 2008; 358(19):1991–2002; doi: 10.1056/NEJMoa0707943
26.
PerssonM, NormanM, HansonU. Obstetric and perinatal outcomes in type 1 diabetic pregnancies: A large, population-based study. Diabetes Care, 2009; 32(11):2005–2009; doi: 10.2337/dc09-0656
27.
BalsellsM, García-PattersonA, GichI, CorcoyR. Maternal and fetal outcome in women with type 2 versus type 1 diabetes mellitus: A systematic review and metaanalysis. J Clin Endocrinol Metab, 2009; 94(11):4284–4291; doi: 10.1210/jc.2009-1231
28.
MurphyHR, SteelSA, RolandJM, et al.; East Anglia Study Group for Improving Pregnancy Outcomes in Women with Diabetes (EASIPOD). Obstetric and perinatal outcomes in pregnancies complicated by Type 1 and Type 2 diabetes: Influences of glycaemic control, obesity and social disadvantage. Diabet Med, 2011; 28(9):1060–1067; doi: 10.1111/j.1464-5491.2011.03333.x
29.
WuY, LiuB, SunY, et al.Association of maternal prepregnancy diabetes and gestational diabetes mellitus with congenital anomalies of the newborn. Diabetes Care, 2020; 43(12):2983–2990; doi: 10.2337/dc20-0261
30.
HildénK, MagnusonA, HansonU, et al.Trends in pregnancy outcomes for women with gestational diabetes mellitus in Sweden 1998–2012: A nationwide cohort study. Diabet Med, 2020; 37(12):2050–2057; doi: 10.1111/dme.14266
SweetingA, HannahW, BackmanH, et al.Epidemiology and management of gestational diabetes. Lancet, 2024; 404(10448):175–192; doi: 10.1016/S0140-6736(24)00825-0
34.
KampmannU, KnorrS, FuglsangJ, OvesenP. Determinants of maternal insulin resistance during pregnancy: An updated overview. J Diabetes Res, 2019; 2019:5320156; doi: 10.1155/2019/5320156
LydonK, DunneFP, OwensL, et al.Psychological stress associated with diabetes during pregnancy: A pilot study. Ir Med J, 2012; 105(5 Suppl):26–28.
38.
EganAM, DunneFP, LydonK, et al.Diabetes in pregnancy: Worse medical outcomes in type 1 diabetes but worse psychological outcomes in gestational diabetes. QJM, 2017; 110(11):721–727; doi: 10.1093/qjmed/hcx106
39.
CarolanM, GillGK, SteeleC. Women’s experiences of factors that facilitate or inhibit gestational diabetes self-management. BMC Pregnancy Childbirth, 2012; 12:99; doi: 10.1186/1471-2393-12-99
40.
Asiedu-DansoM, KretchyIA, SekyiJK, KoduahA. Adherence to antidiabetic medications among women with gestational diabetes. J Diabetes Res, 2021; 2021:9941538; doi: 10.1155/2021/9941538
41.
Feitosa AC, Sampaio LN, Batista AG, Pinheiro CB. Frequency of fear of needles and impact of a multidisciplinary educational approach towards pregnant women with diabetes. Revista Brasileira De Ginecologia e Obstetrícia, 2013; 35(3):111–116; doi: 10.1590/S0100-72032013000300004
42.
PaschouSA, ShalitA, GerontitiE, et al.Efficacy and safety of metformin during pregnancy: An update. Endocrine, 2024; 83(2):259–269; doi: 10.1007/s12020-023-03550-0
43.
DunneF, NewmanC, Alvarez-IglesiasA, et al.Metformin and small for gestational age babies: Findings of a randomised placebo-controlled clinical trial of metformin in gestational diabetes (EMERGE). Diabetologia, 2024; 67(12):2660–2666; doi: 10.1007/s00125-024-06252-y
44.
FeigDS, DonovanLE, ZinmanB, et al.; MiTy Collaborative Group. Metformin in women with type 2 diabetes in pregnancy (MiTy): A multicentre, international, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol, 2020; 8(10):834–844; doi: 10.1016/S2213-8587(20)30310-7
45.
RowanJA, RushEC, PlankLD, et al.Metformin in gestational diabetes: The offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7-9 years of age. BMJ Open Diabetes Res Care, 2018; 6(1):e000456; doi: 10.1136/bmjdrc-2017-000456
46.
PaavilainenE, NiinikoskiH, ParkkolaR, et al.Metformin versus insulin for gestational diabetes: Adiposity variables and adipocytokines in offspring at age of 9 years. Diabetes Res Clin Pract, 2023; 202:110780; doi: 10.1016/j.diabres.2023.110780
47.
SwensonKS, WangD, JonesAK, et al.Metformin disrupts signaling and metabolism in fetal hepatocytes. Diabetes, 2023; 72(9):1214–1227; doi: 10.2337/db23-0089
48.
BolteE, DeanT, GarciaB, et al.Initiation of metformin in early pregnancy results in fetal bioaccumulation, growth restriction, and renal dysmorphology in a primate model. Am J Obstet Gynecol, 2024; 231(3):352.e1–352.e16; doi: 10.1016/j.ajog.2024.06.002
49.
MurphyHR, ElleriD, AllenJM, et al.Pathophysiology of postprandial hyperglycaemia in women with type 1 diabetes during pregnancy. Diabetologia, 2012; 55(2):282–293; doi: 10.1007/s00125-011-2363-6
50.
RickertMC, BarbourLA, BodeBW, et al.Inhaled insulin in pregnancy: A case series supporting feasibility and clinical potential for pregnant people with diabetes. Pregnancy, 2025; 1(5):e70065; doi: 10.1002/pmf2.70065
51.
SlatteryD, AmielSA, ChoudharyP. Optimal prandial timing of bolus insulin in diabetes management: A review. Diabet Med, 2018; 35(3):306–316.
McGillJB, PetersA, BuseJB, et al.Comprehensive pulmonary safety review of inhaled technosphere® insulin in patients with diabetes mellitus. Clin Drug Investig, 2020; 40(10):973–983; doi: 10.1007/s40261-020-00958-8
54.
HallGC, RobertsCM, BoulisM, et al.Diabetes and the risk of lung cancer. Diabetes Care, 2005; 28(3):590–594; doi: 10.2337/diacare.28.3.590
BjornstadP, DartA, DonaghueKC, et al.ISPAD Clinical Practice Consensus Guidelines 2022: Microvascular and macrovascular complications in children and adolescents with diabetes. Pediatr Diabetes, 2022; 23(8):1432–1450; doi: 10.1111/pedi.13444
59.
Foti RandazzeseS, La RoccaM, BombaciB, et al.Severe diabetic ketoacidosis in children with type 1 diabetes: Ongoing challenges in care. Children (Basel), 2025; 12(1):110; doi: 10.3390/children12010110
60.
PoovazhagiV. Risk factors for mortality in children with diabetic keto acidosis from developing countries. World J Diabetes, 2014; 5(6):932–938; doi: 10.4239/wjd.v5.i6.932
61.
BonadioW. The evaluation and management of pediatric diabetic ketoacidosis: A comprehensive review. Clin Pediatr (Phila), 2023; 62(6):551–564; doi: 10.1177/00099228221139982
62.
RamaeshA. Incidence and long-term outcomes of adult patients with diabetic ketoacidosis admitted to intensive care: A retrospective cohort study. J Intensive Care Soc, 2016; 17(3):222–233; doi: 10.1177/1751143716644458
63.
KostopoulouE, SinopidisX, FouzasS, et al.Diabetic ketoacidosis in children and adolescents; diagnostic and therapeutic pitfalls. Diagnostics (Basel), 2023; 13(15):2602; doi: 10.3390/diagnostics13152602
64.
VirdiN, PoonY, AbanielR, BergenstalRM. Prevalence, cost, and burden of diabetic ketoacidosis. Diabetes Technol Ther, 2023; 25(S3):S75–S84; doi: 10.1089/dia.2023.0149
65.
EdgeJA, HawkinsMM, WinterDL, DungerDB. The risk and outcome of cerebral oedema developing during diabetic ketoacidosis. Arch Dis Child, 2001; 85(1):16–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11420189
66.
GlaserN, BarnettP, McCaslinI, et al.; Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. Risk factors for cerebral edema in children with diabetic ketoacidosis. The Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. N Engl J Med, 2001; 344(4):264–269; doi: 10.1056/NEJM200101253440404
67.
GhettiS, KuppermannN, RewersA, et al.; Pediatric Emergency Care Applied Research Network (PECARN) DKA FLUID Study Group. Cognitive function following diabetic ketoacidosis in children with new-onset or previously diagnosed type 1 diabetes. Diabetes Care, 2020; 43(11):2768–2775; doi: 10.2337/dc20-0187
68.
LiuCC, ChenKR, ChenHF, et al.Trends in hospitalization for diabetic ketoacidosis in diabetic patients in Taiwan: Analysis of national claims data, 1997-2005. J Formos Med Assoc, 2010; 109(10):725–734; doi: 10.1016/S0929-6646(10)60117-9
69.
NyenweE, LoganathanR, BlumS, et al.Admissions for diabetic ketoacidosis in ethnic minority groups in a city hospital. Metabolism, 2007; 56(2):172–178; doi: 10.1016/j.metabol.2006.09.010
70.
HammersenJ, TittelSR, WarnckeK, et al.; DPV Initiative. Previous diabetic ketoacidosis as a risk factor for recurrence in a large prospective contemporary pediatric cohort: Results from the DPV initiative. Pediatr Diabetes, 2021; 22(3):455–462; doi: 10.1111/pedi.13185
71.
HillH, KlaarP, EspesD. Real-life data of hypoglycemic events in children and adolescents with type 1 diabetes. BMJ Open Diabetes Res Care, 2023; 11(5):e003485; doi: 10.1136/bmjdrc-2023-003485
72.
UrakamiT. Severe hypoglycemia: Is it still a threat for children and adolescents with type 1 diabetes? Front Endocrinol (Lausanne), 2020; 11:609; doi: 10.3389/fendo.2020.00609
73.
AbitbolL, PalmertMR. When low blood sugars cause high anxiety: Fear of hypoglycemia among parents of youth with type 1 diabetes mellitus. Can J Diabetes, 2021; 45(5):403–410.e2; doi: 10.1016/j.jcjd.2020.08.098
74.
WildD, von MaltzahnR, BrohanE, et al.A critical review of the literature on fear of hypoglycemia in diabetes: Implications for diabetes management and patient education. Patient Educ Couns, 2007; 68(1):10–15; doi: 10.1016/j.pec.2007.05.003
75.
DabasH, SarinJ, MadhuSV. Insulin adherence in adolescents with type 1 diabetes mellitus. Indian J Endocrinol Metab, 2023; 27(5):394–397; doi: 10.4103/ijem.ijem_294_22
76.
BesserREJ, BellKJ, CouperJJ, et al.ISPAD clinical practice consensus guidelines 2022: Stages of type 1 diabetes in children and adolescents. Pediatr Diabetes, 2022; 23(8):1175–1187; doi: 10.1111/pedi.13410
77.
ElhenawyYI, AbdelmageedRI, ZaafarDK, AbdelazizAW. Adherence to insulin therapy among children with type 1 diabetes: Reliability and validity of the arabic version of the 4-item Morisky medication adherence scale. Patient Prefer Adherence, 2022; 16:1415–1421; doi: 10.2147/PPA.S341061
78.
CramerJA. Systematic review of adherence with medications for diabetes. Diabetes Care, 2004; 27(5):1218–1224; doi: 10.2337/diacare.27.5.1218
79.
MillerKM, FosterNC, BeckRW, et al.; T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the U.S.: Updated data from the T1D exchange clinic registry. Diabetes Care, 2015; 38(6):971–978.
80.
FosterNC, BeckRW, MillerKM, et al.State of Type 1 Diabetes management and outcomes from the T1D Exchange in 2016–2018. Diabetes Technol Ther, 2019; 21(2):66–72.
81.
EbekozienO, MungmodeA, SanchezJ, et al.Longitudinal trends in glycemic outcomes and technology use for over 48,000 people with type 1 diabetes (2016–2022) from the T1D exchange quality improvement collaborative. Diabetes Technol Ther, 2023; 25(11):765–773; doi: 10.1089/dia.2023.0320
82.
FarsaeiS, RadfarM, HeydariZ, et al.Insulin adherence in patients with diabetes: Risk factors for injection omission. Prim Care Diabetes, 2014; 8(4):338–345; doi: 10.1016/j.pcd.2014.03.001
83.
HoweCJ, RatcliffeSJ, TuttleA, et al.Needle anxiety in children with type 1 diabetes and their mothers. MCN Am J Matern Child Nurs, 2011; 36(1):25–31; doi: 10.1097/NMC.0b013e3181fc6093
84.
CemerogluAP, CanA, DavisAT, et al.Fear of needles in children with type 1 diabetes mellitus on multiple daily injections and continuous subcutaneous insulin infusion. Endocr Pract, 2015; 21(1):46–53; doi: 10.4158/EP14252.OR
85.
ZhangL, XuH, LiuL, et al.Related factors associated with fear of hypoglycemia in parents of children and adolescents with type 1 diabetes - A systematic review. J Pediatr Nurs, 2022; 66:125–135; doi: 10.1016/j.pedn.2022.05.022
86.
HaugstvedtA, Wentzel-LarsenT, GraueM, et al.Fear of hypoglycaemia in mothers and fathers of children with type 1 diabetes is associated with poor glycaemic control and parental emotional distress: A population-based study. Diabet Med, 2010; 27(1):72–78.
87.
FreckletonE, SharpeL, MullanB. The relationship between maternal fear of hypoglycaemia and adherence in children with type-1 diabetes. Int J Behav Med, 2014; 21(5):804–810; doi: 10.1007/s12529-013-9360-8
Di BattistaAM, HartTA, GrecoL, GloizerJ. Type 1 diabetes among adolescents. Diabetes Educ, 2009; 35(3):465–475; doi: 10.1177/0145721709333492
90.
ChaoAM, MingesKE, ParkC, et al.General life and diabetes-related stressors in early adolescents with type 1 diabetes. J Pediatr Health Care, 2016; 30(2):133–142; doi: 10.1016/j.pedhc.2015.06.005
91.
PompiliM, ForteA, LesterD, et al.Suicide risk in type 1 diabetes mellitus: A systematic review. J Psychosom Res, 2014; 76(5):352–360; doi: 10.1016/j.jpsychores.2014.02.009
92.
GonçalvesS, BarrosV, Rui GomesA. Eating-disordered behaviour in adolescents with type 1 diabetes. Can J Diabetes, 2016; 40(2):152–157; doi: 10.1016/j.jcjd.2015.09.011
93.
KokkonenJ, LautalaP, SalmelaP. The state of young adults with juvenile onset diabetes. Int J Circumpolar Health, 1997; 56(3):76–85.
94.
MajidiS, O’DonnellHK, StanekK, et al.Suicide risk assessment in youth and young adults with type 1 diabetes. Diabetes Care, 2020; 43(2):343–348; doi: 10.2337/dc19-0831
95.
HillRM, GallagherKAS, EshtehardiSS, et al.Suicide risk in youth and young adults with type 1 diabetes: A review of the literature and clinical recommendations for prevention. Curr Diab Rep, 2021; 21(12):51; doi: 10.1007/s11892-021-01427-y
96.
Renaud-CharestO, Stoljar GoldA, MokE, et al.Suicidal ideation, suicide attempts, and suicide deaths in adolescents and young adults with type 1 diabetes: A systematic review and meta-analysis. Diabetes Care, 2024; 47(7):1227–1237; doi: 10.2337/dc24-0411
97.
HoodKK, HuestisS, MaherA, et al.Depressive symptoms in children and adolescents with type 1 diabetes: Association with diabetes-specific characteristics. Diabetes Care, 2006; 29(6):1389–1391.
98.
LawrenceJM, StandifordDA, LootsB, et al.; SEARCH for Diabetes in Youth Study. Prevalence and correlates of depressed mood among youth with diabetes: The SEARCH for Diabetes in Youth study. Pediatrics, 2006; 117(4):1348–1358; doi: 10.1542/peds.2005-1398
99.
ChenZ, WangJ, CarruC, et al.The prevalence of depression among parents of children/adolescents with type 1 diabetes: A systematic review and meta-analysis. Front Endocrinol (Lausanne), 2023; 14:1095729; doi: 10.3389/fendo.2023.1095729
100.
DavisEA, ShettyVB, TeoSYM, et al.Physical activity management for youth with type 1 diabetes: Supporting active and inactive children. Diabetes Spectr, 2023; 36(2):137–145; doi: 10.2337/dsi22-0020
101.
HallerMJ, KanapkaL, MonzaviRet al.INHALE-1: A Multicenter Randomized Trial of Inhaled Technosphere Insulin in Children With Type 1 Diabetes. Diabetes Care, 2025; doi: 10.2337/dc25-1994, 41223151
CarlinerH, BrownQL, SarvetAL, HasinDS. Cannabis use, attitudes, and legal status in the U.S.: a review. Prev Med, 2017; 104:13–23; doi: 10.1016/j.ypmed.2017.07.008
105.
SannegowdaR, VillalbaK, SukR, et al.Recent rates of substance use among adolescents and young adults with type 1 diabetes in the USA. Curr Diab Rep, 2023; 23(1):1–17; doi: 10.1007/s11892-022-01496-7
KinneyGL, AkturkHK, TaylorDD, et al.Cannabis use is associated with increased risk for diabetic ketoacidosis in adults with type 1 diabetes: Findings From the T1D exchange clinic registry. Diabetes Care, 2020; 43(1):247–249; doi: 10.2337/dc19-0365
108.
AkturkHK, TaylorDD, CamsariUM, et al.Association between cannabis use and risk for diabetic ketoacidosis in adults with type 1 diabetes. JAMA Intern Med, 2019; 179(1):115–118; doi: 10.1001/jamainternmed.2018.5142
